Shulou(Shulou.com)06/02 Report--

Author: Li Yuchen 2020-06-12 17:16 topic: special topic of the two sessions: new infrastructure leads post-epidemic economic introduction: the future thinking of medical AI head enterprises will affect the final trend of the industry to a great extent.

According to the annual report on global artificial intelligence investment trends released by CB Insights, global artificial intelligence start-ups raised $26.6 billion in 2019, while health care accounted for $4 billion, which remains one of the hottest areas for AI landing.

On the other hand, in 2020, the pace of construction of "new infrastructure" begins to accelerate.

Prior to this, Beijing, Fujian, Henan, Yunnan, Guangdong, Jiangsu and other places have issued a list of major project investment plans for 2020. According to incomplete statistics, the total scale of investment plans for "new infrastructure" in various localities has exceeded 40 trillion yuan.

Medical care is closely related to people's life and health, and "medical treatment plus new infrastructure" has naturally received special attention. Artificial intelligence is an important part of the new infrastructure. Cutting into the leading enterprises in the medical industry with artificial intelligence, such as Keya Healthcare, inferential Technology, Huiyi Huiying, voxel Technology, has naturally become the "backbone" of this wave of construction.

A common feature of these companies is that almost all of them were founded at the same time (2016), which is called the first year of artificial intelligence. Blowing all the sand to gold, more than four years, they have proved their technical and commercial strength to the industry.

At the end of the 19th century and the beginning of the 20th century, the Italian economist Pareto put forward the "twenty-eight law", also known as the key minority rule, which is also applicable to the medical AI industry.

The future thinking of medical AI head enterprises will affect the trend of the industry to a great extent.

Keya Medical: using three kinds of certificates to correct the name of the industry

As the first company in the medical AI industry to get the medical AI class III certificate, Keya Medical really boosted the confidence of the medical AI industry in January this year.

Keya Medical said that the new medical infrastructure is a smart medical construction process based on the medical big data platform and a new generation of medical information network, with artificial intelligence technology as the core driving force.

Under the influence of the "new infrastructure", the medical AI industry will pay more attention to the following three aspects in the future:

First, the clinical value of the product: the core purpose of medical AI technology is to serve the clinic, so the clinical value of the product in the whole clinical process will become an important principle to test the value of the product.

Second, the validity of the results: in fact, medical AI is to intelligently collect, manage and analyze multi-dimensional full-cycle data, and then realize many functions such as discovery, early warning, assistant decision-making, and so on, and the feedback on the effectiveness of the results of these functions will also become the only standard for verifying the product.

Third, product compliance: the launch of the new infrastructure has given the medical AI industry many opportunities, and at the same time, it must also introduce a supporting management mechanism, so product compliance, as the quasi-test and threshold of the industry, will become particularly important.

Lei Feng learned that at present, the first product of Keya Medical is the "Coronary flow Reserve fraction calculation Software (Deep vein fraction ®)".

"Deep vein score" is the first artificial intelligence type III medical device registered and approved by the State Drug Administration (NMPA) in China, and it is also the only domestic product with dual certification of Chinese NMPA and EU CE. In the announcement, the State Drug Administration qualitatively evaluated it with "significant economic and social benefits". At present, there are no products of the same variety registered and listed in China.

The deep pulse score adopts the depth learning technology pioneered exclusively by Keya Medical, which intelligently optimizes all aspects from medical image processing, model reconstruction to FFR calculation, which effectively reduces the influence of image noise and artifacts, improves the accuracy and accuracy of segmentation, and greatly improves the processing speed.

Compared with the current screening method based solely on observing the degree of CTA stenosis (lumen diameter stenosis rate ≥ 50%), the diagnostic accuracy and specificity of deep vein score (FFR 88.6% vs CTA 30% 40%), positive predictive value and negative predictive value are significantly improved, which can effectively reduce the probability of false positive.

Keya Medical said that the clinical application of deep pulse scores will benefit patients, hospitals, society, and so on:

For patients, deep vein score, with the characteristics of non-invasive, accurate, convenient and efficient, is beneficial to early diagnosis and repeated reexamination, avoids excessive treatment (unnecessary invasive coronary angiography and follow-up PCI treatment), and relieves patients' surgical pain and economic pressure.

For doctors, it is necessary to embed deep vein scores into doctors' existing workflows to take over tedious, repetitive and low-value data screening behaviors, so as to help doctors quickly and accurately extract valuable information from clinical data and obtain true and accurate quantitative evaluation indicators, so as to help formulate individual treatment plans and promote the speed and efficiency of medical processes.

For the society, deep vein score can greatly save medical resources and medical expenses, reduce social medical costs, and has significant economic and social benefits.

At present, Keya Medical has cooperated with more than 200 large-scale third-level first-class hospitals, including Beijing Anzhen Hospital affiliated to Capital Medical University, PLA Air Force General Hospital, Qilu Hospital of Shandong University, Southwest Hospital of the third military Medical University and Guangdong Provincial people's Hospital, to build "Deep vein score artificial Intelligence diagnosis Center". A series of vascular function evaluation products around the circulatory system and an intelligent imaging platform for imaging department have been developed.

Centering on the "new medical infrastructure", in the coming year, Keya Medical will focus on the clinical application of clinical medical artificial intelligence technology, accelerate the expansion of the application of AI medical products from medical technology departments to various clinical departments, integrate multi-group information, including medical records, imaging, pathology, biochemistry, immunity, molecular diagnosis, and so on, to serve multiple clinical application scenarios such as early screening, diagnosis and treatment. Truly realize the coverage of the whole process of single disease.

Speculative science and technology: two "masterpieces" to devote themselves to the new medical infrastructure

Chen Kuan, founder and CEO of science and technology, believes that the new medical infrastructure will have a tremendous impact on the medical industry, especially the construction of medical infrastructure, and will strengthen infrastructure construction in clinical, graded diagnosis and treatment, public health, and other areas, with a more efficient and powerful response capacity.

Take the epidemic situation of COVID-19 as an example, the emergence of artificial intelligence and other new technologies has greatly enhanced the ability of monitoring, case screening, diagnosis and treatment of COVID-19 's epidemic situation, and provided great help for rapid response and control of the epidemic.

At present, it is assumed that there are medical products and solutions in many areas, among which there are two "masterpieces".

The first is a hypothetical technology pneumonia intelligent screening and epidemic surveillance system.

When COVID-19 's epidemic hit, inference Technology worked with a number of top hospitals in Wuhan to iterate and optimize the algorithm for COVID-19 's special image performance. On the one hand, the system can quickly help doctors to detect lesions and early warning, avoid missed diagnosis and reduce the risk of cross-infection in hospital for the rapid detection of suspected cases of COVID-19.

On the other hand, through intelligent quantitative analysis of abnormal cases and severe cases, the progress and curative effect of confirmed cases can be monitored and evaluated, which can predict critically ill patients and provide help for COVID-19 patients to treat them more timely and accurately.

According to Lei Feng Network, the system has not only been widely used in medical institutions in Wuhan, Hubei and even the whole country, but also immediately transferred China's war epidemic experience and capabilities to Japan, Italy, the United States, Germany and other countries through AI, helping many countries around the world to fight the epidemic.

After more than four years of development, the presumed AI products have been granted EU CE access and Japan PMDA access successively, while the global epidemic continues, and the global market value of this product will be further highlighted.

The second is the research platform of InferScholar AI scholars.

This is an integrated device of software and hardware, which provides zero code, full-process deep learning and imaging model research and incubation tools, and provides a full-stack intelligent research infrastructure for medical researchers.

According to Lei Feng net, this platform uses full interface operation to create a visual big data analysis tool for medical researchers and gives medical researchers the ability to carry out high-level scientific research who do not have the ability of computer programming. It can deal with XR, CT, MR, PET, ultrasound, pathology and other full-mode image data in all directions. The scope of the study covers the intelligent analysis of disease images of whole organs such as brain, chest, abdomen and whole body bone tissue, especially for early disease diagnosis, treatment monitoring and prognosis prediction.

At present, the platform has been applied in many top hospitals across the country.

Chen Kuan said that scientific research originates from the clinic and is applied to the clinic. The infrastructure of medical research platform based on artificial intelligence technology is part of the new medical infrastructure, which will play a more important value and role under the drive of the new infrastructure.

It is worth noting that on June 9, speculation Technology released a new and upgraded brand image.

Chen Kuan said that this move is to comply with the development trend of "new infrastructure", to create a new brand of medical AI new infrastructure with the imprint of speculation, and to form an international medical AI brand.

He said that in the future, it is speculated that medical AI will effectively improve the capabilities of basic medical screening, diagnosis and treatment in the strategic path of the country's new infrastructure; at the same time, it will dig deep into medical scenes, rely on the mining of clinical pathways for single diseases, and continue to promote the expansion of pan-AI precision medical applications of multi-disease, multi-department, multi-scene and multi-demand.

Huiyi Huiying: three major product systems to open the closed loop of medical process

Huiyi Huiying CEO Chai Xiangfei said that the new medical infrastructure needs to complete the construction of the whole project from regional imaging system, digital intelligent film, intelligent assistant diagnosis, remote image diagnosis, medical big data decision support system, interface development service, platform support, etc., reflecting the practical application value of intelligent medicine.

Generally speaking, medical care is a heavy regulatory industry, both the use and charging links are related to superior supervision.

Whether it is drugs, devices, or artificial intelligence, wearable, 3D printing and other new technologies in the medical field, roughly need to go through five stages.

First, it is necessary to form an expert consensus and be recognized by experts in the industry; second, to rely on experts to form expert guides; third, to get approval from the FDA; fourth, to approve prices so as to charge hospitals; fifth, on the basis of deep landing, enter the scope of medical insurance, making the application service from self-expense to public expense reimbursement.

Chai Xiang Fei to Lei Feng net (official account: Lei Feng net) said that the smart medical industry has formed a good expert consensus in 2018, and this year may break through the third stage, that is, the approval of the FDA. Overseas also attaches great importance to access qualifications.

Recently, Huiyi Huiying multi-disease imaging AI medical products have been certified by EU CE. The system includes lung CT image-assisted diagnosis system, fracture-assisted diagnosis system, chest X-ray auxiliary diagnosis system and so on.

He added that in China, artificial intelligence has been included in a number of disease treatment guidelines this year, and the next step is to form a separate charge, that is, to obtain price permits, before a large-scale commercial process can be officially launched. Policies related to the new infrastructure will promote this process and speed up the landing pace of medical AI.

According to Lei Feng Network, at present, Huiyi Huiying has constructed three major product systems: NovaCloudTM intelligent image cloud platform, Dr. TuringTM artificial intelligence aided diagnosis platform and RadCloudTM big data artificial intelligence research platform, creating digital, mobile and intelligent medical images, completing the closed loop from screening, diagnosis and treatment decision support, data-driven, and realizing the whole process coverage from scientific research to clinic.

Up to now, Huiyi Huiying products and services have been applied in more than 1000 medical institutions, including more than 300 third-class hospitals. In the field of medical imaging artificial intelligence research, Huiyi Huiying has undertaken and participated in more than 20 national and provincial scientific research projects.

In 2019, Huiyi Huiying upgraded its strategy and launched an overall solution for smart imaging, with continuous investment and layout in smart medicine, smart hospitals, intelligent scientific research, big data and artificial intelligence applications.

Chai Xiangfei said that next, Huiyi Huiying will closely follow the idea of "new infrastructure" and continue to increase technology research and development and market investment. it will continue to improve the full-cycle product solution of medical image artificial intelligence, which can open up the information flow, workflow and data flow, accelerate the landing of hospitals, assist hospitals and the government to establish an intelligent platform for the whole process of imaging medicine, and provide customers with more mature and reliable technical and service support.

At the same time, we will continue to deepen our in-depth cooperation with Huawei, Intel and other partners to build a new scene of smart imaging medical services and achieve an interconnected and healthy China.

Voxel Science and Technology: the idea of "all kinds of Diseases" runs through all the time

Ding Xiaowei, CEO of voxel technology, believes that the construction of new medical infrastructure can start from encouraging medical informatization, Internet medical care, artificial intelligence + medical treatment, and other aspects, in which medical informatization is the infrastructure of the modern medical industry, while in this epidemic, Internet medical care and artificial intelligence + medical industry have played an important role, including artificial intelligence CT film reading, online consultation, graded diagnosis and treatment, telemedicine and other services.

"the new medical infrastructure can introduce these technology-driven tools into the medical field, providing digital and intelligent support for the basic elements of the medical field, including hospital facilities, doctors, diagnosis and treatment equipment, etc."

Through the promotion of new medical infrastructure, especially the introduction of 5G, artificial intelligence and data center technology, it will have a great impact on the medical AI industry. Among them, the construction of big data center, digital transformation and intelligent upgrading can bring more data and more powerful computing power.

Artificial intelligence itself is part of the new infrastructure, and many project opportunities will emerge through development; in addition, the connection, landing and transformation after infrastructure can make various products more organically integrated into the diagnosis and treatment work.

In this epidemic, several all-disease products of voxel technology have played an important role.

When the epidemic broke out in February, the voxel R & D team upgraded the chest CT imaging screening solution for all diseases to a special edition of pneumonia, and was immediately admitted to Shanghai Ruijin Hospital and the first people's Hospital to provide auxiliary film reading services for doctors to screen out suspected pneumonia patients, prompting doctors to focus on observation, greatly reducing the pressure on doctors at work.

In addition, voxel skin Zhihui, a self-examination product for all kinds of skin diseases, has played a huge role on the Internet medical platform. On Tencent's health home page, more than 200000 users use the Mini Program to self-check for skin problems online every day. Tens of millions of people have experienced it so far.

In addition, voxel ophthalmology screening products are not only online in more than 300 MMC, but also landed in township health centers across the country, so that the most grass-roots people can use the latest artificial intelligence tools to contribute to the popularization of eye health medical knowledge at the grass-roots level.

Ding Xiaowei told Lei Feng that in the future, voxel technology will continue to make efforts in medical informatization, Internet medical care, and artificial intelligence medical care, continue to deepen technological research and development and product optimization, achieve more flexible deployment methods, and enter more hospitals.

At the same time, we will continue to improve the integration of the upstream and downstream of the product line, build the whole process from intelligent devices to auxiliary diagnosis platform services and then to personal health management, collect and obtain more medical clinical evidence, and verify the improvement of efficiency after construction.

Https://www.leiphone.com/news/202006/fP5yoTBEfzjVPeM3.html

Welcome to subscribe "Shulou Technology Information " to get latest news, interesting things and hot topics in the IT industry, and controls the hottest and latest Internet news, technology news and IT industry trends.